Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Lymphocytic Leukaemia: Update Bulletin [April 2015]

Product Code:
596200423
Release Date:
April 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Chronic Lymphocytic Leukaemia.  Topics covered: Imbruvica opportunities and key updates, the likely outcome of the RESONATE-2 trial,  the design and likelihood for success of the Phase III HELIOS trial and views on combining Imbruvica with AbbVie’s ABT 199 as a treatment for CLL.

Key Questions Answered in this Update Bulletin:

  • What opportunities exist within the CLL treatment paradigm for AbbVie to recover its investment in Imbruvica?
  • In which CLL patients and settings will the use of Imbruvica increase in the near to medium term? Will Imbruvica use move earlier in the CLL treatment algorithm?
  • How do KOLs view the commercial and clinical rationale for the first-line use of Imbruvica in CLL?
  • What are the major threats to the growth of Imbruvica and the return on AbbVie’s investment?
  • How do KOLs view the use of Imbruvica for the treatment of 17p-deleted CLL and will use in this setting fuel further growth of Imbruvica?
  • How do KOLs view the likely outcome of the RESONATE-2 trial and how will it influence first-line uptake of Imbruvica?
  • To what extent is Imbruvica’s use in heavily pre-treated CLL patients following allogeneic stem cell transplantation expected to potentially drive revenue growth?
  • How do KOLs view the design and likelihood for success of the Phase III HELIOS trial?
  • How do KOLs view combining Imbruvica with AbbVie’s ABT 199 as a treatment for CLL?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved